Exicure Announces Board and Committee Changes

Rhea-AI Summary

Exicure (Nasdaq:XCUR) announced Board and committee changes effective June 30, 2026, following a June 24 special meeting.

Jung Kyu Ham resigned as director. Jin Young Go and Eui Seok Han were appointed Class III directors, expanding the Board from five to six members. The Board affirmed Nasdaq independence compliance and updated Audit and Compensation Committee memberships.

News Market Reaction – XCUR

-5.45%

7 alerts

-5.45% Session close to close

+19.0% Peak Tracked

-15.7% Trough Tracked

$15.93M Market Cap

1.5x Rel. Volume

In the Jun 30 session, XCUR declined 5.45%, reflecting a notable negative market reaction. Argus tracked a peak move of +19.0% during that session. Argus tracked a trough of -15.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.5% in the session following this news. A negative reaction despite positive news ...

Analysis

The stock moved -5.5% in the session following this news. A negative reaction despite positive news fits a market focused on Exicure’s fragile balance sheet and Nasdaq risks rather than governance tweaks. Board and committee enhancements may be seen as necessary but insufficient without clearer funding and listing visibility.

Key Figures

Special board meeting date: June 24, 2026 Effective date: June 30, 2026 Board size before change: 5 directors +3 more

6 metrics

Special board meeting date June 24, 2026 Date board approved director and committee changes

Effective date June 30, 2026 Effective date of resignations and new appointments

Board size before change 5 directors Size of Board prior to June 30, 2026 changes

Board size after change 6 directors New Board size following appointment of an additional director

Audit Committee members 3 members Yoon Tae Han (Chair), Dongho Lee, Gyeong Seog Cheon

Compensation Committee members 2 members Committee comprised of Eui Seok Han (Chair) and Dongho Lee

Historical Context

5 past events · Latest: Jun 10 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 10	Nasdaq equity notice	Negative	+2.2%	Nasdaq notice for falling below the $2.5M minimum stockholders’ equity requirement.
Jun 01	Nasdaq filing notice	Neutral	-6.6%	Late Form 10-Q triggered a delinquency notice, then filing restored perceived compliance.
Apr 22	Co-development deal	Positive	+0.1%	Co-development agreement with Adbiotech for Burixafor across several hematologic indications.
Mar 25	Full-year results	Negative	+0.0%	2025 results highlighting shrinking cash, ongoing losses and going‑concern uncertainties.
Feb 05	Clinical publication	Positive	+4.4%	Phase 2 burixafor data showing rapid stem cell mobilization and generally good tolerability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows inconsistent price responses, including a gain on negative Nasdaq equity news and only modest moves on clinical and partnership updates.

Key Terms

independent director, nasdaq listing rules, audit committee, compensation committee, +1 more

5 terms

independent director regulatory

"the Board determined that Eui Seok Han qualifies as an independent director"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

nasdaq listing rules regulatory

"independent director under the Nasdaq Listing Rules"

Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.

audit committee financial

"confirmed the composition of its Audit Committee, which will continue to consist of"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

compensation committee financial

"the Board established a Compensation Committee comprised of Eui Seok Han"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

form 8-k regulatory

"included in the Company's Current Report on Form 8-K to be filed"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026.

The Company's Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.

The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham's resignation. In addition, the Board approved an increase in the size of the Board from five to six directors and appointed Eui Seok Han as a Class III director to fill the newly created directorship. Both appointments are effective June 30, 2026.

Following a review of the applicable Nasdaq independence standards, the Board determined that Eui Seok Han qualifies as an independent director under the Nasdaq Listing Rules. Following these changes, the Company continues to satisfy the Nasdaq requirement that a majority of its Board consist of independent directors.

The Board also confirmed the composition of its Audit Committee, which will continue to consist of Yoon Tae Han (Chair), Dongho Lee and Gyeong Seog Cheon. In addition, the Board established a Compensation Committee comprised of Eui Seok Han (Chair) and Dongho Lee, effective June 30, 2026.

Additional information regarding these matters will be included in the Company's Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company's lead program is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company's corporate governance, Board composition and strategic direction. Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Media Contact

Exicure, Inc.

pr@exicuretx.com

FAQ

What Board changes did Exicure (XCUR) announce on June 30, 2026?

Exicure announced the resignation of director Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as Class III directors. According to Exicure, these moves follow a June 24, 2026 special Board meeting.

Who replaced Jung Kyu Ham on the Exicure (XCUR) Board and when is it effective?

Jin Young Go was appointed a Class III director to fill the vacancy created by Jung Kyu Ham’s resignation. According to Exicure, the appointment and resignation are effective June 30, 2026.

How did Exicure (XCUR) change the size of its Board in June 2026?

Exicure’s Board size increased from five to six directors with the appointment of Eui Seok Han as a Class III director. According to Exicure, this newly created directorship is effective June 30, 2026.

Is new Exicure (XCUR) director Eui Seok Han considered independent under Nasdaq rules?

Exicure’s Board determined that Eui Seok Han qualifies as an independent director under Nasdaq Listing Rules. According to Exicure, the company continues to meet Nasdaq’s requirement that a majority of directors be independent.

What is the composition of Exicure (XCUR)’s Audit Committee after the June 2026 changes?

Exicure confirmed its Audit Committee will continue to consist of Yoon Tae Han (Chair), Dongho Lee, and Gyeong Seog Cheon. According to Exicure, this committee structure remains in place following the June 30, 2026 Board changes.

Did Exicure (XCUR) establish a new Compensation Committee in June 2026?

Yes. Exicure created a Compensation Committee composed of Eui Seok Han (Chair) and Dongho Lee. According to Exicure, the Compensation Committee becomes effective June 30, 2026, aligning with the broader Board and governance updates.